

REMARKS/ARGUMENTS


Claims 1, 21 and 22 are pending. By this Amendment, claim 20 is cancelled, and claims 1, 21 and 22 are amended. Support for the amendments to claims 1, 21 and 22 can be found, for example, in original claims 1 and 20-22. No new matter is added. In view of the foregoing amendments and following remarks, reconsideration and allowance are respectfully requested.

Rejection Under 35 U.S.C. §102


The Office Action rejects claims 1 and 20-22 under 35 U.S.C. §102(b) over U.S. Patent No. 6,534,199 to Hosokawa et al. ("Hosokawa"). By this Amendment, claim 20 is cancelled, rendering the rejection moot as to that claim. As to the remaining claims, Applicants respectfully traverse the rejection.

Claim 1 is set forth above. Hosokawa does not disclose or suggest such an electroluminescence device.

Hosokawa discloses three arylamines that are arguably comparable to the arylamines of claim 1, which do not include a styryl group or a styrylene group:



The compounds EM3, EM25 and EM26 have the following residues corresponding to the residue X<sup>3</sup> in formula (V) of claim 1:



(i.e., the portion between the arylamine groups).

Claim 1 explicitly specifies that the residue  $X^3$  in formula (V) is derived from naphthalene, phenanthrene, fluoranthene, anthracene, pyrene, perylene, coronene, chrysene, picene, diphenylanthracene, fluorene, triphenylene, rubicene, benzoanthracene, phenylanthracene, bisanthracene, dianthracenylbenzene or dibenzoanthracene, each being substituted or unsubstituted. The particular residues shown above, which are included in the compounds EM3, EM25 and EM26 of Hosokawa, and correspond to the residue  $X^3$  in formula (V) of claim 1, do not satisfy this definition of  $X^3$  set forth in claim 1.

As Hosokawa fails to disclose or suggest an electroluminescence device including an arylamine compound according to formula (V) of claim 1, in which the compound does not include and  $X^3$  is limited to residues derived from naphthalene, phenanthrene, fluoranthene, anthracene, pyrene, perylene, coronene, chrysene, picene, diphenylanthracene, fluorene, triphenylene, rubicene, benzoanthracene, phenylanthracene, bisanthracene, dianthracenylbenzene or dibenzoanthracene, each being substituted or unsubstituted, Hosokawa fails to disclose or suggest each and every feature of claim 1.

As explained, claim 1 is not anticipated by Hosokawa. Claims 21 and 22 depend from claim 1 and, thus, also are not anticipated by Hosokawa. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

#### Double Patenting

The Office Action rejects claims 1 and 20-22 under the judicially created doctrine of obviousness-type double patenting over claims 1 and 4 of Hosokawa. By this Amendment,

claim 20 is cancelled, rendering the rejection moot as to that claim. As to the remaining claims, Applicants respectfully traverse the rejection.

Component A of claims 1 and 4 of Hosokawa is a styrylamine. As discussed above, the arylamines of claim 1 of the present application do not include a styryl group or a styrylene group. The claims of Hosokawa do not recite or suggest an arylamine that is free from styryl groups or styrylene groups. Accordingly, claims 1 and 4 of Hosokawa fail to render obvious claim 1 of the present application. Claims 21 and 22 depend from claim 1 and, thus, claims 1 and 4 of Hosokawa also fail to recite or suggest each and every feature of claims 21 and 22.


Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

#### Conclusion

For the foregoing reasons, Applicants submit that claims 1, 21 and 22 are in condition for allowance. Prompt reconsideration and allowance are respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



---

Jacob A. Doughty  
Registration No. 46,671

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 08/07)